62 results about "Low-density lipoprotein" patented technology

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention discloses a composition with an auxiliary blood fat reducing effect as well as a preparation method and application thereof, and relates to the technical field of medicines. In the composition disclosed by the invention, the hawthorn, the lotus leaf, the mulberry leaf and the algae oil are mutually matched for use and have a synergistic effect, so that the effects of remarkably reducing the body weight, reducing the content of low-density lipoprotein, the content of Apo-B and the content of GLU in blood and improving indexes of high-density lipoprotein and Apo-A1 are achieved. The composition is applied to preparation of the blood fat reducing medicine and / or health food, and the blood fat reducing effect is stable.

The present invention relates to a Korean microbiome-derived Clostridium butyricum strain having anti-obesity efficacy and a use thereof. The strain has an excellent effect of reducing the body weight and adipose tissue weight of experimental animals compared to a control group (strain-untreated) under high-fat diet conditions, has an excellent effect of reducing the content of total cholesterol, triglycerides, low-density lipoprotein (LDL), leptin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum, and has an excellent effect of reducing blood glucose and increasing the content of glucagon-like peptide-1 (GLP-1) in an oral glucose load test, and is thus expected to be effectively used as an ingredient in a composition for preventing, alleviating, or treating obesity and metabolic diseases caused by obesity.

The invention belongs to the technical field of biological detection, and particularly relates to a detection method and a detection kit for oxidized low-density lipoprotein. The invention provides a novel application of quaternary ammonium salt chitosan in a kit, and particularly relates to application of quaternary ammonium salt chitosan with different molecular weights in an immunoturbidimetry detection process of oxidized low-density lipoprotein. When high-molecular-weight quaternized chitosan with the molecular weight of 100-200 kDa and low-molecular-weight quaternized chitosan with the molecular weight of 30-50 kDa are used as components of the oxidized low-density lipoprotein detection kit, the quaternized chitosan with different molecular weights can react with citrate radicals to form gel particles with different mechanical strengths; the content of the oxidized low-density lipoprotein can be detected through immunoturbidimetry, and the sensitivity and the linear range of the oxidized low-density lipoprotein detection kit are greatly improved and widened by using the quaternized chitosan with different molecular weights.

The invention belongs to the technical field of medical materials, and particularly relates to an adsorption material for removing low-density lipoprotein as well as a preparation method and application of the adsorption material. The adsorption material comprises a carrier and a ligand immobilized on the carrier, wherein the carrier is obtained by grafting and modifying polymer microspheres through glycidyl methacrylate, and the polymer microspheres comprise at least one of polystyrene divinyl benzene resin microspheres and polymethacrylate resin microspheres; the ligand contains a group with negative electricity.

Compositions and methods for treating rheumatoid arthritis and / or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

This invention belongs to the field of traditional Chinese medicine technology. More specifically, it relates to the application of a processed product of Citrus reticulata peel or Citrus reticulata peel embryo (with bitterness removed) in the preparation of products for lowering lipids and preventing and treating hyperlipidemia. Compared with the original product, the processed product of Citrus reticulata peel or Citrus reticulata peel embryo provided by this invention significantly reduces bitterness while significantly enhancing its effects in lowering cholesterol and triglycerides and regulating blood lipids. This processed product helps maintain normal levels of serum cholesterol, triglycerides, and low-density lipoprotein, and can significantly improve liver damage caused by hyperlipidemia, thus having important application value in lowering lipids and protecting the liver.

The application belongs to the technical field of traditional Chinese medicine exosomes, and particularly relates to mulberry-derived extracellular vesicle particles, a preparation method thereof and application thereof in the preparation of medicines for preventing and treating hyperlipidemia and related symptoms. The mulberry-derived extracellular vesicle particles provided by the application are prepared by using mulberries as raw materials, centrifuging the mulberries at different centrifugal speeds after juice extraction, and then performing density gradient centrifugation with a sucrose solution with a specific density. Experimental research shows that the mulberry-derived extracellular vesicle particles can significantly reduce total cholesterol, triglyceride and low-density lipoprotein in blood, inhibit the formation of aortic plaques caused by hyperlipidemia and lipid deposition in the liver, and are safe and non-toxic, and therefore can be used for the preparation of medicines for preventing and treating hyperlipidemia and related symptoms.

The application discloses a composition for improving blood lipid metabolism, which comprises the following raw materials: sweet cinnamon powder, rhodiola powder, roxburgh rose powder and curcuma zedoaria powder. The preparation method of the composition for improving blood lipid metabolism comprises the following steps: screening the sweet cinnamon powder, the rhodiola powder, the roxburgh rose powder and the curcuma zedoaria powder respectively, mixing them uniformly to obtain mixed powder; adding sterile deionized water into the mixed powder to obtain a mixed solution; adding a complex enzyme into the mixed solution for enzymolysis; after the enzymolysis is completed, the enzyme is inactivated, filtration is conducted, and the filtrate is freeze-dried to obtain the composition for improving blood lipid metabolism. The plant powder is subjected to mixed enzymolysis through multiple enzymes, the natural active substances in the plant powder are enriched, and the types of the enzymolysis products are enriched, so that the total cholesterol, the triglyceride and the low-density lipoprotein content in blood can be reduced, and the high-density lipoprotein content in blood can be increased.

The present invention relates to a composition for alleviating obesity or improving lipid metabolism, comprising a Rostellularia procumbens extract. The Rostellularia procumbens extract according to the present invention has the effects of inhibiting weight gain and fat accumulation and lowering blood levels of total triglycerides, total cholesterol, and low-density lipoprotein. In addition, the Rostellularia procumbens extract of the present invention, as a natural medicinal agent, can be applied to various products such as pharmaceutical compositions, food compositions, and feed compositions for the prevention, treatment, or alleviation of obesity or for the improvement of lipid metabolism.

This invention discloses a method for preparing filler particles for targeted adsorption of low-density lipoprotein (LDL) in patients with atherosclerosis. The steps include: 1) washing D101 macroporous resin with ultrapure water and physiological saline; 2) adding fibrin and PBS solution for soaking; adding thrombin factor II; adding zinc gluconate during the reaction; 3) repeating step 2) at least three times and drying the D101 macroporous resin; 4) adding physiological saline and D101 macroporous resin to lyophilized protein ApoB100 and mixing thoroughly; 5) lyophilizing the resin obtained in step 4) while controlling the humidity at 65±5% to obtain the finished product. This application utilizes this adhesion effect to target the adsorption of foam cells in atherosclerosis, adsorbing foam cells through hemoperfusion, removing redundant blood lipid components in the body, reducing macrophage infiltration of organs and blood vessels, and reducing pathological changes in organs and blood vessels.

The application belongs to the technical field of diagnostic markers, and particularly relates to a pathological diagnosis biomarker combination for adrenal Cushing syndrome and application. The pathological diagnosis biomarker combination comprises low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl coenzyme A synthetase 1 (HMGCS1) and cytochrome P450 11B1 (CYP11B1). The area under the ROC curve (AUC) of the pathological diagnosis biomarker combination can reach 0.881 (95% confidence interval (CI): 0.775-987; sensitivity: 85.7%; specificity: 85.0%), which indicates that the combination of LDLR, HMGCS1 and CYP11B1 as the pathological diagnosis biomarker combination for adrenal Cushing syndrome has high accuracy.

The invention belongs to the technical field of experimental animals, and particularly relates to application of reserpine in construction of animal models with normal high and low density lipoprotein and triglyceride values. The animal model construction method is minimally invasive, low in cost and good in reproducibility, has remarkable western medicine clinical biochemical index characteristics and a clear action mechanism, and can successfully and repeatedly establish an animal model with high and low density lipoprotein and normal triglyceride values. Conditions are created for clinical research on pathogenesis of related diseases, diagnosis and treatment of related diseases and screening, research and treatment of related disease mechanisms and drugs thereof, and good application prospects are achieved.

The invention provides a low density lipoprotein electrophoresis typing method and a gel electrophoresis separation column for electrophoresis typing, the gel electrophoresis separation column comprises a concentrated gel and a separation gel, the concentrated gel and the separation gel both comprise acrylamide, N, N-dimethacrylamide, cane sugar, glycerin and a Tris-HCl solution, the content of acrylamide in the separation gel is 1.42-1.53 times that of the concentrated gel, the content of the N, N-dimethacrylamide in the separation gel is 1.42-1.53 times that of the Tris-HCl solution, and the content of the N, N-dimethacrylamide in the separation gel is 1.42-1.53 times that of the Tris-HCl solution in the separation gel. And the content of N, N-bis (methacrylamide) in the separation gel is 1.41-1.52 times that in the concentrated gel. The electrophoresis typing method provided by the invention has the advantages of simplicity and convenience in operation, rapidness, high efficiency, high sensitivity, good resolution ratio and low cost.

The present disclosure features antibodies and antibody fragments capable of binding to oxidized-low density lipoprotein, wherein the antibody is conjugated to a detectable label. The disclosure also provides methods for using the antibodies conjugated to a detectable label to detect the presence for atherosclerotic plaques in a subject as well as methods for diagnosing a subject with a cardiovascular disease.

The invention provides pediococcus acidilactici XZFMCC101.23156, a microbial preparation, an antibacterial composition and application of the pediococcus acidilactici XZFMCC101.23156, and belongs to the technical field of functional microorganisms. The preservation number of the pediococcus acidilactici XZFMCC101.23156 is GDMCC No: 66860, and the pediococcus acidilactici XZFMCC101.23156 can be used as a functional microbial agent to be applied in vivo to improve diseases such as hyperlipidemia and the like, and can also achieve the effect of reducing body weight. The result of the embodiment shows that the culture supernatant of the pediococcus acidilactici XZFMCC101.23156 can effectively reduce the total cholesterol, the triglyceride, the low-density lipoprotein and the high-density lipoprotein in a rat body. The pediococcus acidilactici XZFMCC101.23156 provides a new way for the development of oral probiotic preparations and the preparation of foods, drinks, health care products and medicines with the function of degrading cholesterol.

The invention provides a fermentation composition with a heart and cerebral vessel protection effect, a preparation method and application. The composition is prepared from raw materials consisting of radix ophiopogonis, radix puerariae and black sesame according to a specific ratio through sequential fermentation of plant lactobacillus KU01 and lactobacillus reuteri HX-LRE501. The preparation method is characterized in that KU01 is inoculated for first-stage hydrolysis fermentation, then pH is adjusted, and HX-LRE501 is inoculated for second-stage directional synthesis fermentation. According to the process, active ingredients such as conjugated linoleic acid and soluble polysaccharide are efficiently enriched through bacterial strain function synergy. The fermentation composition can effectively regulate blood fat, inhibit generation of oxidized low-density lipoprotein, relieve inflammation and regulate an intestinal flora structure through a multi-target synergistic effect, so that the anti-atherosclerosis effect is achieved. The composition is safe in raw materials, stable in process and suitable for large-scale production, and has a definite application prospect in preparation of foods or medicines for preventing and / or improving atherosclerosis and related cardiovascular and cerebrovascular diseases.

Methods and compositions for the treatment of atherosclerosis or cardiovascular disease are provided herein. The compositions and methods contain a nanoparticle-peptide conjugate that reduces LDL concentration in a subject, reduces reactive oxygen species in the subject, or increases cellular healing rate.

The invention discloses a blood fat reducing compound based on sea cucumber peptide as well as a preparation method and application thereof, and belongs to the technical field of health food. The compound comprises the following raw materials: sea cucumber peptide, a zingiber mioga bud aqueous extract, a dandelion aqueous extract, an industrial hemp leaf aqueous extract and vitamin C. The components are compounded according to a specific ratio, and the components generate a remarkable synergistic effect and jointly act on a plurality of links of lipid metabolism. The compound can remarkably reduce the levels of serum total cholesterol (TC), triglyceride (TG) and low-density lipoprotein (LDL) of hyperlipidemia model mice, meanwhile, the level of high-density lipoprotein (HDL) is increased, the blood fat reducing effect of the compound is superior to that of a single component and a positive control drug, and the compound is high in safety. The invention also provides a preparation method of the compound and application of the compound in preparation of drugs or health-care foods for prevention and / or adjuvant therapy of hyperlipidemia.

This invention belongs to the fields of biomedical materials and colloid chemistry, and discloses a structurally remodeled egg yolk low-density lipoprotein biomimetic liposome and its application in regulating cholesterol metabolism. The method includes extracting and purifying natural egg yolk low-density lipoprotein; selectively removing endogenous cholesterol by adding β-cyclodextrin under alkaline conditions; adding a phytosterol ethanol solution to the cholesterol-removed low-density lipoprotein dispersion, followed by incubation and dialysis purification to obtain the biomimetic liposome. The obtained biomimetic liposome uses partially cholesterol-removed egg yolk low-density lipoprotein as its structural framework, with phytosterols embedded in its phospholipid monolayer and lipid core interface. This biomimetic liposome can inhibit cholesterol micelle formation, reduce cholesterol absorption, promote macrophage cholesterol efflux, and inhibit macrophage foam formation. It can be used to prepare cholesterol metabolism regulating materials, functional delivery systems, and dietary supplement products.

The invention discloses characteristics and application of aerial microalgae Pilidiocystis sp. FDA-4 with high yield of C18, and belongs to the technical field of microalgae biology. The aerial microalgae FDA-4 is preserved in the China Center for Type Culture Collection on July 1, 2025, and the preservation number of the aerial microalgae FDA-4 is CCTCC NO: M 20251502. The strain has excellent low-pH adaptability and organic acid tolerance, can be directly cultured by using lactic acid bacteria waste liquid as the unique carbon source and nutrient medium, the optimal dilution ratio is 100 times, the biomass reaches 0.19 g / L after 12 days of culture, an exogenous nitrogen source does not need to be added and the initial pH does not need to be adjusted, the fatty acid composition is mainly C18 series, and the strain has a wide application prospect. The produced grease can be used for preparing products for reducing the low-density lipoprotein level and preventing cardiovascular diseases; meanwhile, the strain can efficiently convert nutrient substances in the lactic acid bacteria waste liquid, resource utilization of the waste liquid is achieved, and the strain has remarkable application value and industrialization potential.

The present application relates to a low-density lipoprotein low-speed centrifugal separation and purification method, comprising the following steps: using human serum, plasma and the remaining plasma after extracting other proteins as raw materials, adding PEG6000 to precipitate plasma low-density lipoprotein, then adding NaCl to adjust the liquid density and centrifugal, repeating the process, gradually changing the concentration and ratio of PEG6000 and NaCl until the plasma low-density lipoprotein precipitates and floats on the surface of the liquid after centrifugation, thereby separating from other proteins. The present application has the advantages of simple operation, large processing capacity, easy-to-get and cheap and safe reagents, low equipment requirements, high yield, and provides a convenient condition for various studies of plasma low-density lipoprotein.

The invention discloses an apolipoprotein B (ApoB) antibody related to oxidized low density lipoprotein (Ox-LDL) or a functional fragment of the apolipoprotein B antibody, and an application of the apolipoprotein B antibody and the functional fragment. The anti-Ox-ApoB antibody or the functional fragment thereof disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, and the antibody or the functional fragment thereof has relatively good specificity and sensitivity to Ox-ApoB, and can be used for detecting Ox-ApoB and / or Ox-LDL and used for auxiliary diagnosis of atherosclerosis by taking Ox-ApoB and / or Ox-LDL as a marker.

The invention discloses a fluorescent probe for detecting peroxynitrite ions as well as a preparation method and application thereof, and relates to the technical field of biomedical detection, and the structural formula of the fluorescent probe is shown in the specification. The prepared fluorescent probe for detecting the peroxynitrite ions has high selectivity and high sensitivity on the peroxynitrite ions, the response speed is high, fluorescence stability can be achieved within about 30 minutes, ratio type fluorescent quantitative detection of the peroxynitrite ions in an aqueous solution is achieved, the linear correlation is good, and the detection sensitivity is high. The rapid detection of the peroxynitrite ion level in an oxidation modified low-density lipoprotein induced atherosclerosis cell model is also realized, and good biocompatibility and application potential are realized.

Methods for identifying chronic hydrocephalus include assaying for an amount in a biological sample of one or more biomarkers selected from pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4), phosphofructokinase-muscle (PFKM), low density lipoprotein receptor adaptor protein 1 (LDLRAP1), glucagon-like peptide-1 receptor (GLP-1R), hemoglobin subunit alpha 1 (HBA1), hemoglobin subunit alpha 2 (HBA2), heme oxygenase 1 (HMOX1), and combinations thereof. Methods for screening for a compound useful for treating chronic hydrocephalus are also provided and include contacting a cell with an effective amount of a test compound, and then detecting an expression or activity level of one or more of the biomarkers.

A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.

The present invention includes compositions and methods for treating atherosclerosis. In certain embodiments, atherosclerosis is treated using a chimeric antigen receptor (CAR) T cell specific for modified low-density lipoprotein.